Track record · closed signal

Abbott Laboratories (ABT) — closed signal from April 2, 2026

Partial Published before the outcome was known, scored automatically when the window closed on July 1, 2026 — -9.9% at the close.

Predicted vs. what happened

ABT price · publication thesis → realized outcomesplit-adjusted

$100.00 – $103.50Entry zone — fair-value band

$102.30Published — price the day we called it

$113.55Target — the price the thesis aimed for

$103.84Peak — highest point inside the window, not a realized return

$92.18Window close — end-of-window price, context only

What happened

Partial

Reached 14% of the predicted growth at its peak, without hitting the target.

At window close

-9.9%

realized, from the publication price to the last close inside the window

Peak gain

+1.5%

peak, from the publication price — not a realized return

S&P 500, same window

+14%

SPY over the identical days, dividend-adjusted

Window close

$92.18

last close inside the window, ended July 1, 2026

Peak price

$103.84

peak on April 8, 2026 — not a realized return

Days to target

—

The thesis — published April 2, 2026

Predicted growth

+11%

over the measurement window

Target price

$113.55

the price the thesis aimed for

Entry zone

$100.00 – $103.50

the fair-value band we waited for

Price at publication

$102.30

published April 2, 2026

Confidence

72%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Shares have fallen more than peers, yet the company still shows financial strength and recent news about a digital-health stake gives the story a fresher growth angle. The stake in Whoop helps connect Abbott to faster-growing areas, but that alone is not the full investment case. We view this as an early potential rebound, not a clear momentum winner.

Primary drivers

Price weakness opens the chance for a defensive bounce
Broad business mix helps protect against big drops
Investment in Whoop adds a faster-growth storyline
Strong balance sheet reduces financial stress risk

How it played out

ABT: the rebound thesis did not play out

Lyra published ABT at $102.30 with an 11% expected gain and a $113.55 target. The thesis expected an early rebound after relative price weakness. It pointed to Abbott's broad business mix, strong balance sheet, and investment in Whoop as support for a faster-growth angle, while acknowledging that momentum was not yet clear.

ABT rose only as high as $103.84 on April 8, a peak gain of 1.5%. It never reached the target. By July 1, the shares had fallen to $92.18. The published rebound thesis did not play out within the measurement window.

What happened during the window

On April 16, Abbott reported first-quarter adjusted earnings per share of $1.15 and updated its full-year guidance. On May 27, Abbott announced European approval for its dual glucose-ketone sensor.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All ABT signals